{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:55:58Z","timestamp":1784735758148,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00393-024-01549-0","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T16:52:00Z","timestamp":1724431920000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccination status of patients with primary immunodeficiencies in Germany\u2014a\u00a0multicentric epidemiologic analysis","Impfstatus von Patienten mit prim\u00e4rer Immundefizienz in Deutschland \u2013 eine multizentrische epidemiologische Analyse"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1935-2092","authenticated-orcid":false,"given":"Eva C.","family":"Schwaneck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9481","authenticated-orcid":false,"given":"Anna S.","family":"Harasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Gawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-0267","authenticated-orcid":false,"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-529X","authenticated-orcid":false,"given":"Stefanie","family":"Joos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-4459","authenticated-orcid":false,"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5819-726X","authenticated-orcid":false,"given":"Henner","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-3903","authenticated-orcid":false,"given":"Matthias","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1020-6454","authenticated-orcid":false,"given":"Manuel","family":"Krone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"1549_CR1","unstructured":"Immunisation schedule of the standing committee on vaccination. www.stiko.de (2020\/2021)"},{"key":"1549_CR2","unstructured":"(2021) Epidemiologisches Bulletin 34. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/34\/Tabelle.html"},{"key":"1549_CR3","unstructured":"Tuberkuloseimpfung in Deutschland? https:\/\/www.rki.de\/SharedDocs\/FAQ\/Impfen\/Tuberkulose\/FAQ01.html"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s00103-018-2807-y","volume":"61","author":"S Ehl","year":"2018","unstructured":"Ehl\u00a0S, Bogdan\u00a0C, Niehues\u00a0T, Burchard\u00a0G, Baumann\u00a0U, Hecht\u00a0J et\u00a0al (2018) Impfen bei Immundefizienz. Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (II)\u00a0Impfen bei 1. Prim\u00e4ren Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsbl 61:1034\u20131051","journal-title":"Bundesgesundheitsbl"},{"issue":"4","key":"1549_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","volume":"133","author":"WT Shearer","year":"2014","unstructured":"Medical Advisory Committee of the Immune Deficiency F, Shearer\u00a0WT, Fleisher\u00a0TA, Buckley\u00a0RH, Ballas\u00a0Z, Ballow\u00a0M et\u00a0al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J\u00a0Allergy Clin Immunol 133(4):961\u2013966","journal-title":"J Allergy Clin Immunol"},{"issue":"5\u20136","key":"1549_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00103-013-1693-6","volume":"56","author":"C Poethko-M\u00fcller","year":"2013","unstructured":"Poethko-M\u00fcller\u00a0C, Schmitz\u00a0R (2013) Impfstatus von Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt 56(5\u20136):845\u2013857","journal-title":"Bundesgesundheitsblatt"},{"issue":"32","key":"1549_CR7","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1016\/j.vaccine.2015.06.056","volume":"33","author":"K Grabmeier-Pfistershammer","year":"2015","unstructured":"Grabmeier-Pfistershammer\u00a0K, Herkner\u00a0H, Touzeau-Roemer\u00a0V, Rieger\u00a0A, Burgmann\u00a0H, Poeppl\u00a0W (2015) Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine 33(32):3929\u20133932","journal-title":"Vaccine"},{"issue":"6","key":"1549_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/cid\/ciu979","volume":"60","author":"MD Durham","year":"2015","unstructured":"Durham\u00a0MD, Buchacz\u00a0K, Armon\u00a0C, Pragna Patel, Wood\u00a0KJTB (2015) Seasonal Influenza Vaccination Rates in the HIV Outpatient Study\u2014United States, 1999\u20132013. Clin Infect Dis 60(6):976\u2013977","journal-title":"Clin Infect Dis"},{"issue":"35","key":"1549_CR9","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1016\/j.vaccine.2014.06.015","volume":"32","author":"F Valour","year":"2014","unstructured":"Valour\u00a0F, Cotte\u00a0L, Voirin\u00a0N, Godinot\u00a0M, Ader\u00a0FTF, Ader\u00a0FTF (2014) Vaccination coverage against hepatitis\u00a0A and\u00a0B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 32(35):4558\u20134564","journal-title":"Vaccine"},{"issue":"31","key":"1549_CR10","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1016\/j.vaccine.2015.06.012","volume":"33","author":"P Loubet","year":"2015","unstructured":"Loubet\u00a0P, Kern\u00e9is\u00a0S, Groh\u00a0M, Loulergue\u00a0P, Blanche\u00a0P, Verger\u00a0P et\u00a0al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a\u00a0large cohort of patients with secondary immune deficiency. Vaccine 33(31):3703\u20133708","journal-title":"Vaccine"},{"key":"1549_CR11","unstructured":"According to the Germany ministry of health. https:\/\/www.bundesgesundheitsministerium.de\/gkv.html"},{"issue":"1","key":"1549_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10875-021-01160-x","volume":"42","author":"S Hosaka","year":"2022","unstructured":"Hosaka\u00a0S, Kido\u00a0T, Imagawa\u00a0K, Fukushima\u00a0H, Morio\u00a0T, Nonoyama\u00a0S et\u00a0al (2022) Vaccination for Patients with Inborn Errors of Immunity: a\u00a0Nationwide Survey in Japan. Clin Immunol 42(1):183\u2013194","journal-title":"Clin Immunol"},{"key":"1549_CR13","unstructured":"Robert Koch-Institut (2021) Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch-Institut. Epid Bull 2021(34)"},{"key":"1549_CR14","doi-asserted-by":"publisher","DOI":"10.25646\/4839","author":"Robert Koch-Institut","year":"2018","unstructured":"Robert Koch-Institut (2018) Aktuelles aus der KV-Impfsurveillance\u2014Impfquoten ausgew\u00e4hlter Schutzimpfungen in Deutschland. Epid Bull. https:\/\/doi.org\/10.25646\/4839","journal-title":"Epid Bull"},{"key":"1549_CR15","volume-title":"HPV-Impfquoten im Regionalvergleich: Eine Sekund\u00e4rdatenanalyse aus der KV-Impfsurveillance","author":"T Rieck","year":"2016","unstructured":"Rieck\u00a0T, Feig\u00a0M, Wichmann\u00a0O (2016) HPV-Impfquoten im Regionalvergleich: Eine Sekund\u00e4rdatenanalyse aus der KV-Impfsurveillance (versorgungsatlas.de)"},{"key":"1549_CR16","unstructured":"Lohse T, Wild F, Jacke CO Impfung gegen humane Papillomaviren (HPV): Eine Analyse der Arzneimittelverordnungsdaten in der PKV\u20142006 bis 2016. Wissenschaftliches Inst Pkv 2019:"},{"key":"1549_CR17","first-page":"1","volume":"1","author":"T Rieck","year":"2017","unstructured":"Rieck\u00a0T, Feig\u00a0M, Wichmann\u00a0O, Siedler\u00a0A (2017) Impfquoten der Rotavirus\u2011, Masern\u2011, HPV- und Influenza-Impfung in Deutschland. Epid Bull 1:1\u201312. https:\/\/doi.org\/10.17886\/EpidBull-2017\u2013001","journal-title":"Epid Bull"},{"issue":"18","key":"1549_CR18","first-page":"147","volume":"2019","author":"Robert Koch-Institut","year":"2017","unstructured":"Robert Koch-Institut (2017) Impfquoten bei der Schuleingangsuntersuchung in Deutschland. Epid Bull 2019(18):147\u2013153","journal-title":"Epid Bull"},{"issue":"3","key":"1549_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/6843","volume":"2020","author":"Robert Koch-Institut","year":"2019","unstructured":"Robert Koch-Institut (2019) Evaluation der Varizellen-Impfempfehlung durch die St\u00e4ndige Impfkommission (STIKO). Epid Bull 2020(3):3\u201315. https:\/\/doi.org\/10.25646\/6843","journal-title":"Epid Bull"},{"issue":"33","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.25646\/7044","volume":"32","author":"Robert Koch-Institut","year":"2020","unstructured":"Robert Koch-Institut (2020) Impfquoten von Kinderschutzimpfungen in Deutschland\u2014ak-tuelle Ergebnisse aus der RKI-Impfsurveillance. Epid Bull 32(33):9\u201327. https:\/\/doi.org\/10.25646\/7044","journal-title":"Epid Bull"},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12887-019-1729-7","volume":"19","author":"W Jinhong","year":"2019","unstructured":"Jinhong\u00a0W, Wenwei\u00a0Z, Yin\u00a0Y, Hao\u00a0Z (2019) Primary immunodeficiency disease: a\u00a0retrospective study of 112 Chinese children in a\u00a0single tertiary care center. BMC Pediatr 19:410","journal-title":"BMC Pediatr"},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"789345","DOI":"10.3389\/fimmu.2021.789345","volume":"12","author":"M Gernert","year":"2021","unstructured":"Gernert\u00a0M, Kiesel\u00a0M, Fr\u00f6hlich\u00a0M, Renner\u00a0R, Strunz\u00a0PP, Portegys\u00a0J, Tony\u00a0HP, Schmalzing\u00a0M, Schwaneck\u00a0EC (2021) High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies. Front Immunol 12:789345","journal-title":"Front Immunol"},{"issue":"8","key":"1549_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/RHU.0000000000000866","volume":"25","author":"JP Dhar","year":"2019","unstructured":"Dhar\u00a0JP, Essenmacher\u00a0L, Dhar\u00a0R, Ragina\u00a0N, Sokol\u00a0RJ (2019) Lack of Uptake of Prophylactic Human Papilloma Virus Vaccine Among Women With Systemic Lupus Erythematosus Seen at a\u00a0Regional Medical Center. J\u00a0Clin Rheumatol 25(8):348\u2013350","journal-title":"J Clin Rheumatol"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00393-017-0410-5","volume":"77","author":"M Krasselt","year":"2018","unstructured":"Krasselt\u00a0M, Baerwald\u00a0C, Seifert\u00a0O (2018) Insufficient vaccination rates in patients with systemic lupus erythematosus in a\u00a0German outpatient clinic. Z\u00a0Rheumatol 77:727\u2013734","journal-title":"Z Rheumatol"},{"issue":"4","key":"1549_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/vaccines11040760","volume":"11","author":"M Krasselt","year":"2023","unstructured":"Krasselt\u00a0M, Wagner\u00a0U, Seifert\u00a0O (2023) Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases. Vaccines 11(4):760","journal-title":"Vaccines"},{"issue":"4","key":"1549_CR26","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1002\/hsr2.469","volume":"4","author":"B-O Holtz","year":"2021","unstructured":"Holtz\u00a0B\u2011O, Grimm\u00a0A, Axer\u00a0H (2021) Patients\u2019 attitude towards vaccination after Guillain Barr\u00e9 syndrome. Health Sci Rep 4(4):e469","journal-title":"Health Sci Rep"},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.jaut.2021.102743","volume":"125","author":"AG Tzioufas","year":"2021","unstructured":"Tzioufas\u00a0AG, Bakasis\u00a0A\u2011D, Goules\u00a0AV, Bitzogli\u00a0K, Cinoku\u00a0II, Chatzis\u00a0LG et\u00a0al (2021) A\u00a0prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV\u20112 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J\u00a0Autoimmun 125:102743","journal-title":"J Autoimmun"},{"issue":"2","key":"1549_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.autrev.2013.07.007","volume":"13","author":"G Murdaca","year":"2014","unstructured":"Murdaca\u00a0G, Orsi\u00a0A, Span\u00f2\u00a0F, Puppo\u00a0F, Durando\u00a0P, Icardi\u00a0G et\u00a0al (2014) Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 13(2):75\u201384","journal-title":"Autoimmun Rev"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01549-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:22:45Z","timestamp":1738160565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01549-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"1 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.-P.\u00a0Tony has received honoraria for consultation, travel grants, or speaker\u2019s fees from Takeda\/Shire, Pfizer, GSK, Sanofi, and MSD. T.\u00a0Witte has received honoraria for lectures from AstraZeneca, CSL, GSK, Octapharma, Pfizer, Takeda, and CSL Behring. M.\u00a0Gernert received travel grants from AbbVie, Chugai, Eli Lilly, Hexal, Janssen-Cilag, Novartis, and Pfizer and compensation for board memberships from Takeda. M.\u00a0Schmalzing has received compensation for consultancies from Chugai\/Roche, Hexal\/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer\/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, and Lilly; speaker\u2019s fees from Novartis, AbbVie, AstraZeneca, Chugai\/Roche, Janssen-Cilag, Gilead, and Boehringer\/Ingelheim; and travel grants from Chugai\/Roche, Boehringer\/Ingelheim, Celgene, Medac, UCB, and Mylan. H.\u00a0Morbach has received honoraria for speaking at symposia from Shire\/Takeda and CSL Behring and honoraria for consultation from Shire\/Takeda. M.\u00a0Fr\u00f6hlich has received financial support for attending symposia from AbbVie, Novartis, Janssen, Lilly, and Roche. E.C.\u00a0Schwaneck has received honoraria for speaking at symposia, financial support for attending symposia, and research grants and honoraria for consultation from Janssen, Alfasigma, Eli Lilly, Chugai, Roche, Takeda (Shire), AbbVie, Novartis, Pfizer, Otsuka, Medac, Boehringer Ingelheim, Astra Zeneca, and Fresenius. M.\u00a0Krone has received honoraria for consultation from Abbott, GlaxoSmithKline, Pfizer, and Sanofi outside the submitted work. A.S.\u00a0Harasim, M.\u00a0Gawlik, and S.\u00a0Joos declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committees of the University of W\u00fcrzburg (file number 147\/18-sc) and the University of Hanover (file number 8279_BO_K_2019). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}